PBRM1 Mutations as a Predictive Biomarker for Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review

被引:2
|
作者
Castello Dias Carneiro, Andre Paterno [1 ,2 ,5 ]
Marques Monteiro, Fernando Sabino [1 ,3 ,4 ]
Soares, Andrey [1 ,2 ,5 ]
机构
[1] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, RS, Brazil
[2] Hosp Israelita Albert Einstein, Sao Paulo, Brazil
[3] Hosp Santa Lucia, Brasilia, DF, Brazil
[4] Hosp Univ Brasilia, Brasilia, DF, Brazil
[5] Ctr Paulista Oncol, Oncoclin, Sao Paulo, Brazil
关键词
Metastatic renal cell carcinoma (mRCC); immunotherapy; clinical benefit; PBRM1; PATIENTS PTS; CHECKPOINT INHIBITORS; CTLA-4; BLOCKADE; PD-1; ASSOCIATION; NIVOLUMAB; OUTCOMES;
D O I
10.3233/KCA-210111
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
INTRODUCTION: Genomic features linked to prediction of response to immunotherapy in metastatic renal cell carcinoma (mRCC) are still lacking. Protein polybromo-1 (PBRM1) mutations have been studied as a potential biomarker of clinical benefit, with conflicting published data so far. MATERIAL AND METHODS: This systematic review was guided by the standards of the PRISMA statement to identify studies involving mRCC, immunotherapy and mutations in PBRM1. The main objective was to assess the relationship between PBRM1 mutations and response to immune checkpoint inhibitors (ICI) in patients with mRCC. RESULTS: After an initial search that identified 422 studies, 8 studies met the eligibility criteria and were selected for the final analysis. Data are included from 2 trials in the first-line treatment setting, and 6 trials in second- or later treatment lines evaluating the relationship between the presence of PBRM1 mutations and clinical benefit (CB) with ICI treatment. Regarding the first-line treatment setting, the analysis of both studies failed to show any CB in patients with PBRM1 mutations treated with ICI. However, for the second- and later treatment lines, the results were mixed. CONCLUSIONS: PBRM1 mutations may be a potential genomic biomarker to predict response to ICI treatment in patients with mRCC, mainly in second- and later treatment lines, but the existence of conflicting data in the literature highlights an important bias in the studies and the need for additional clinical validation in large, prospective trials.
引用
收藏
页码:79 / 92
页数:14
相关论文
共 50 条
  • [1] The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma
    Kim, Ji-Yeon
    Lee, Se-Hoon
    Moon, Kyung Chul
    Kwak, Cheol
    Kim, Hyeon Hoe
    Keam, Bhumsuk
    Kim, Tae Min
    Heo, Dae Seog
    [J]. JOURNAL OF UROLOGY, 2015, 194 (04): : 1112 - 1119
  • [2] PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers
    Dai, Jiali
    Cui, Yanan
    Liang, Xiao
    Xu, Jiali
    Li, Jun
    Chen, Yu
    Zhang, Erbao
    Guo, Renhua
    [J]. FRONTIERS IN GENETICS, 2023, 13
  • [3] Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
    Carril-Ajuria, Lucia
    Santos, Maria
    Maria Roldan-Romero, Juan
    Rodriguez-Antona, Cristina
    de Velasco, Guillermo
    [J]. CANCERS, 2020, 12 (01)
  • [4] Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma
    Aili, Abudureyimujiang
    Wen, Jie
    Xue, Lixiang
    Wang, Junjie
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] A germline mutation in PBRM1 predisposes to renal cell carcinoma
    Benusiglio, Patrick R.
    Couve, Sophie
    Gilbert-Dussardier, Brigitte
    Deveaux, Sophie
    Le Jeune, Helene
    Da Costa, Melanie
    Fromont, Gaelle
    Memeteau, Francoise
    Yacoub, Mokrane
    Coupier, Isabelle
    Leroux, Dominique
    Mejean, Arnaud
    Escudier, Bernard
    Giraud, Sophie
    Gimenez-Roqueplo, Anne-Paule
    Blondel, Christophe
    Frouin, Eric
    Teh, Bin T.
    Ferlicot, Sophie
    Bressac-de Paillerets, Brigitte
    Richard, Stephane
    Gad, Sophie
    [J]. JOURNAL OF MEDICAL GENETICS, 2015, 52 (06) : 426 - 430
  • [6] Duration of treatment (DOT) with targeted therapies (TT) or immunotherapy (IO) in PBRM1 mutated metastatic renal cell carcinoma (mRCC).
    Dizman, Nazli
    Bergerot, Paulo Gustavo
    Bergerot, Cristiane Decat
    Hsu, Joann
    Pal, Sumanta K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [7] PBRM1 and BAP1 expression in renal cell carcinoma
    Kuthi, L.
    Fallmann, E.
    Jenei, A.
    Posfai, B.
    Maraz, A.
    [J]. VIRCHOWS ARCHIV, 2018, 473 : S44 - S44
  • [8] Immunotherapy for metastatic renal cell carcinoma: A systematic review
    Peinemann, Frank
    Unverzagt, Susanne
    Hadjinicolaou, Andreas V.
    Moldenhauer, Ines
    [J]. JOURNAL OF EVIDENCE BASED MEDICINE, 2019, 12 (04) : 253 - 262
  • [9] Loss of PBRM1 expression is associated with renal cell carcinoma progression
    Pawlowski, Rafal
    Muehl, Sarah M.
    Sulser, Tullio
    Krek, Wilhelm
    Moch, Holger
    Schraml, Peter
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (02) : E11 - E17
  • [10] PBRM1 loss defines distinct tumor phenotype associated with immunotherapy resistance in renal cell carcinoma
    Liu, Xiande
    Kong, Wen
    Peterson, Christine
    McGrail, Daniel
    Anh Hoang
    Zhang, Xuesong
    Truong Lam
    Pilie, Patrick
    Zhu, Haifeng
    Beckermann, Kathryn
    Haake, Scott
    Isgandrova, Sevinj
    Martinez-Moczygemba, Margarita
    Sahni, Nidhi
    Rathmell, W. Kimryn
    Jonasch, Eric
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7